These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 19034753

  • 1. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.
    Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M.
    Ann Clin Psychiatry; 2008; 20(4):209-18. PubMed ID: 19034753
    [Abstract] [Full Text] [Related]

  • 2. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 3. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlreich MM.
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [Abstract] [Full Text] [Related]

  • 4. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
    Vaccarino AL, Evans KR, Sills TL, Kalali AH.
    Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.
    Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
    [Abstract] [Full Text] [Related]

  • 6. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D.
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [Abstract] [Full Text] [Related]

  • 7. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Mar; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 8. Major depression: the importance of clinical characteristics and treatment response to prognosis.
    Katon W, Unützer J, Russo J.
    Depress Anxiety; 2010 Mar; 27(1):19-26. PubMed ID: 19798766
    [Abstract] [Full Text] [Related]

  • 9. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 10. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun 30; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 11. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.
    Int Clin Psychopharmacol; 2011 Mar 30; 26(2):75-83. PubMed ID: 21102344
    [Abstract] [Full Text] [Related]

  • 12. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.
    J Affect Disord; 2009 Jun 30; 115(3):439-49. PubMed ID: 19027961
    [Abstract] [Full Text] [Related]

  • 13. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.
    Int J Clin Pract; 2007 Aug 30; 61(8):1337-48. PubMed ID: 17627710
    [Abstract] [Full Text] [Related]

  • 14. Residual anxiety symptoms in depressed primary care patients.
    McIntyre RS, Konarski JZ, Soczynska JK, Kennedy SH.
    J Psychiatr Pract; 2007 Mar 30; 13(2):125-8. PubMed ID: 17414691
    [Abstract] [Full Text] [Related]

  • 15. Time course of depression-symptom improvement during treatment with duloxetine.
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ.
    Depress Anxiety; 2005 Mar 30; 21(4):170-7. PubMed ID: 16035056
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A.
    Int J Clin Pract; 2006 May 30; 60(5):613-20. PubMed ID: 16700869
    [Abstract] [Full Text] [Related]

  • 17. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
    Perahia DG, Quail D, Gandhi P, Walker DJ, Peveler RC.
    J Affect Disord; 2008 May 30; 108(1-2):33-41. PubMed ID: 17905442
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 May 30; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.
    Clin J Pain; 2009 May 30; 25(6):461-8. PubMed ID: 19542792
    [Abstract] [Full Text] [Related]

  • 20. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD.
    J Psychiatr Res; 2005 Mar 30; 39(2):161-72. PubMed ID: 15589564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.